BR112020004138A2 - pro-adm como marcador de monitoramento terapêutico para pacientes doentes em estado crítico - Google Patents
pro-adm como marcador de monitoramento terapêutico para pacientes doentes em estado crítico Download PDFInfo
- Publication number
- BR112020004138A2 BR112020004138A2 BR112020004138-6A BR112020004138A BR112020004138A2 BR 112020004138 A2 BR112020004138 A2 BR 112020004138A2 BR 112020004138 A BR112020004138 A BR 112020004138A BR 112020004138 A2 BR112020004138 A2 BR 112020004138A2
- Authority
- BR
- Brazil
- Prior art keywords
- sample
- proadm
- fragment
- level
- patient
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17190912.0 | 2017-09-13 | ||
| EP17190912 | 2017-09-13 | ||
| PCT/EP2018/074722 WO2019053115A1 (en) | 2017-09-13 | 2018-09-13 | USE OF PROADM AS A THERAPEUTIC SURVEILLANCE MARKER FOR CRITICALLY PHASE PATIENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020004138A2 true BR112020004138A2 (pt) | 2020-09-08 |
Family
ID=59887050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020004138-6A BR112020004138A2 (pt) | 2017-09-13 | 2018-09-13 | pro-adm como marcador de monitoramento terapêutico para pacientes doentes em estado crítico |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20200300864A1 (https=) |
| EP (2) | EP3682245A1 (https=) |
| JP (4) | JP7329503B2 (https=) |
| CN (2) | CN111065927B (https=) |
| BR (1) | BR112020004138A2 (https=) |
| CA (1) | CA3075440A1 (https=) |
| WO (2) | WO2019053116A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026013199A1 (en) | 2024-07-12 | 2026-01-15 | Cezanne S.A.S. | Clinical immunoassay with early signal measurement |
| CN118976116B (zh) * | 2024-10-22 | 2025-01-24 | 四川大学华西医院 | 琥珀酰明胶在制备腹膜透析液中的用途以及一种含琥珀酰明胶、枸橼酸钠的腹膜透析液 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2570703B1 (fr) | 1984-09-26 | 1988-07-08 | Commissariat Energie Atomique | Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents |
| US4882733A (en) | 1987-03-13 | 1989-11-21 | Ford Aerospace Corporation | Method and apparatus for combining encoding and modulation |
| FR2664699B1 (fr) | 1990-07-13 | 1995-08-18 | Cis Bio Int | Procede d'amplification du signal d'emission d'un compose luminescent. |
| DE69602756T2 (de) | 1995-08-18 | 2000-02-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie |
| KR100425525B1 (ko) | 2000-11-21 | 2004-03-30 | 재단법인서울대학교산학협력재단 | 조산과 태아감염 및 태아손상을 산전 진단하기 위한진단시약 및 진단키트 |
| US6864237B2 (en) * | 2002-05-17 | 2005-03-08 | Ping Wang | Treatment of shock using adrenomedullin and adrenomedullin binding protein-1 |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| CN101208602A (zh) * | 2005-04-15 | 2008-06-25 | 贝克顿迪金森公司 | 脓毒症的诊断 |
| DE102006034142A1 (de) * | 2006-07-24 | 2008-01-31 | B.R.A.H.M.S. Aktiengesellschaft | Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden |
| US9012151B2 (en) * | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
| DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| US8298774B2 (en) | 2007-03-12 | 2012-10-30 | Biomedica Medizinprodukte Gmbh & Co Kg | Diagnosis of septic complications |
| PL2185937T5 (pl) | 2007-09-07 | 2014-12-31 | Univ Zuerich | Sposób wykrywania posocznicy u ludzi |
| ES2486268T3 (es) | 2007-11-16 | 2014-08-18 | Biocartis Nv | Biomarcadores y procedimientos de diagnóstico, predicción y/o pronóstico de septicemia y usos de los mismos |
| JP5989965B2 (ja) * | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| EP2131200A1 (en) * | 2008-06-04 | 2009-12-09 | BRAHMS Aktiengesellschaft | A marker for graft failure and mortality |
| US9229013B2 (en) | 2009-05-05 | 2016-01-05 | B.R.A.H.M.S Gmbh | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
| JP5702371B2 (ja) * | 2009-05-27 | 2015-04-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害 |
| EP2438447B1 (en) | 2009-06-05 | 2015-02-18 | B.R.A.H.M.S GmbH | Detection of bacterial infections in subjects suffering from dyspnea. |
| US8383332B2 (en) | 2009-10-13 | 2013-02-26 | B.R.A.H.M.S. Gmbh | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack |
| EP2545379B1 (en) | 2010-03-08 | 2015-09-30 | B.R.A.H.M.S GmbH | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints |
| WO2012059477A1 (en) | 2010-11-01 | 2012-05-10 | B.R.A.H.M.S Gmbh | Prognosis and risk assessment of patients with non-specific complaints |
| SG11201402362VA (en) * | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| CA2856150A1 (en) * | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
| US11067586B2 (en) * | 2011-11-16 | 2021-07-20 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
| DK2780717T3 (en) * | 2011-11-16 | 2017-02-13 | Sphingotec Gmbh | ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN |
| US10935548B2 (en) | 2011-12-08 | 2021-03-02 | Astute Medical, Inc. | Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2 |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| EP2976646B1 (en) * | 2013-03-20 | 2020-08-19 | sphingotec GmbH | Adrenomedullin to guide therapy of blood pressure decline |
| US9597730B2 (en) * | 2013-04-19 | 2017-03-21 | United Technologies Corporation | Build plate and apparatus for additive manufacturing |
| US20180348235A1 (en) | 2015-11-27 | 2018-12-06 | B.R.A.H.M.S Gmbh | MR-proADM as marker for the extracellular volume status of a subject |
| EP4231018A3 (en) | 2016-07-08 | 2023-11-15 | SphingoTec GmbH | Adrenomedullin for assessing congestion in a subject with acute heart failure |
| CA3033094A1 (en) | 2016-08-09 | 2018-02-15 | B.R.A.H.M.S Gmbh | Histones and/or proadm as markers indicating an adverse event |
-
2018
- 2018-09-13 WO PCT/EP2018/074723 patent/WO2019053116A1/en not_active Ceased
- 2018-09-13 BR BR112020004138-6A patent/BR112020004138A2/pt unknown
- 2018-09-13 WO PCT/EP2018/074722 patent/WO2019053115A1/en not_active Ceased
- 2018-09-13 JP JP2020515677A patent/JP7329503B2/ja active Active
- 2018-09-13 JP JP2020515760A patent/JP7366007B2/ja active Active
- 2018-09-13 EP EP18765656.6A patent/EP3682245A1/en active Pending
- 2018-09-13 US US16/646,637 patent/US20200300864A1/en active Pending
- 2018-09-13 CN CN201880059136.6A patent/CN111065927B/zh active Active
- 2018-09-13 US US16/646,639 patent/US12517138B2/en active Active
- 2018-09-13 EP EP18765657.4A patent/EP3682246A1/en active Pending
- 2018-09-13 CA CA3075440A patent/CA3075440A1/en active Pending
- 2018-09-13 CN CN201880059366.2A patent/CN111094986B/zh active Active
-
2023
- 2023-01-19 JP JP2023006500A patent/JP7544879B2/ja active Active
- 2023-10-10 JP JP2023175415A patent/JP2023181226A/ja not_active Abandoned
-
2025
- 2025-01-17 US US19/027,967 patent/US20250189539A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020111719A3 (https=) | 2021-12-17 |
| JP2020533604A (ja) | 2020-11-19 |
| US20200300864A1 (en) | 2020-09-24 |
| US20250189539A1 (en) | 2025-06-12 |
| EP3682246A1 (en) | 2020-07-22 |
| CN111094986B (zh) | 2023-11-10 |
| WO2019053116A1 (en) | 2019-03-21 |
| JP7366007B2 (ja) | 2023-10-20 |
| CN111065927B (zh) | 2023-10-17 |
| US20200271667A1 (en) | 2020-08-27 |
| EP3682245A1 (en) | 2020-07-22 |
| CN111094986A (zh) | 2020-05-01 |
| WO2019053116A8 (en) | 2022-03-17 |
| JP2023181226A (ja) | 2023-12-21 |
| WO2019053115A1 (en) | 2019-03-21 |
| JP7329503B2 (ja) | 2023-08-18 |
| JP7544879B2 (ja) | 2024-09-03 |
| CN111065927A (zh) | 2020-04-24 |
| US12517138B2 (en) | 2026-01-06 |
| RU2020111719A (ru) | 2021-10-13 |
| JP2023041741A (ja) | 2023-03-24 |
| JP2020537117A (ja) | 2020-12-17 |
| CA3075440A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220187313A1 (en) | Diagnosis or Prognosis of Postsurgical Adverse Events | |
| AU2021251382B2 (en) | Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (SARS) | |
| JP2024091650A (ja) | 多発外傷患者の外傷関連合併症の予後診断のためのｐｒｏ－ａｄｍ | |
| JP2024023615A (ja) | 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ | |
| US20250189539A1 (en) | Sample including pro-adm as a therapy monitoring marker for critcally ill patients | |
| US20240393352A1 (en) | Antibiotic therapy guidance based on procalcitonin in patients with comorbidities | |
| JP2023095851A (ja) | 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ | |
| RU2782305C2 (ru) | Про-адм в качестве маркера мониторинга терапии для критически больных пациентов | |
| RU2788885C2 (ru) | Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками | |
| RU2820944C2 (ru) | Проадм для прогнозирования риска состояния, требующего госпитализации, у пациентов с симптомами инфекционного заболевания | |
| HK40077959A (en) | Pro-adm for therapy monitoring of intensive care unit patients | |
| HK40031519B (en) | Pct and pro-adm as markers for monitoring antibiotic treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |